



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:

GENESTE et al.

Serial No. 10/089,723

Filed: August 19, 2002

For: MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND  
INTEGRIN  $\alpha\upsilon\beta_3$  RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner of Patents and Trademarks, Washington, D.C. 20231, on:

November 26, 2002

Date of Deposit

Monica K. Sims

Person Making Deposit

Monica K. Sims  
Signature

November 26, 2002

Date of Signature

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This subject Information Disclosure Statement is submitted in connection with applicants' continuing duty of disclosure under 37 CFR 1.56.

Listing of Relevant Documents

The relevant documents are listed in the attached Form PTO-1449.

Remarks

The listed references are discussed on page 1 of the specification and were brought to applicants' attention by the attached International Search Report.

U.S. 5,231,024 is the English equivalent of EP 260 610, which is discussed on page 1 of the instant specification.

WO 96/06941 is not available in English, however an English language abstract is contained on the front page of the reference which should meet the concise explanation requirement.

12/4  
RECEIVED  
DEC 08 2002  
TECH CENTER 1600/26000  
P#7

EP 922 768 is not available in English, however a concise explanation of the relevance of the reference is discussed in the attached International Search Report.

Respectfully submitted,

KEIL & WEINKAUF

A handwritten signature in dark ink, appearing to read 'HB Keil', is written over the printed name.

Herbert B. Keil

Reg. No. 18,967

1350 Connecticut Avenue, N.W.  
Washington, D.C. 20036  
(202) 659-0100  
HBK/mks



Form PTO-144

Document Number  
0000051770Application Number  
10/089,161INFORMATION DISCLOSURE CITATION  
IN AN APPLICATIONApplicant  
GENESTE et al.Filing Date  
August 19, 2002Group Art Unit  
1614

(Use several sheets if necessary)

RECEIVED  
DEC 08 2002  
TECH CENTER 1600/2900  
Sheet 8 of 8

## U.S. PATENT DOCUMENTS

Exam. Init.	Document Number	Date	Name	Class	Sub-Class	Filing Date
	5,231,024	7/27/93	Moeller et al.	435	240	
	5,698,195	12/16/97	Le et al.	424	133	

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub-Class	Filing Date
EP 0922 768 ✓	6/16/99	Europe			
WO 96/06941 ✓	3/7/96	PCT			
WO 99/30730 ✓	6/24/99	PCT			
WO 99/31061 ✓	6/24/99	PCT			
WO 99/26945 ✓	6/3/99	PCT			
WO 97/29131	8/14/97	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Moeller et al. "Monoclonal Antibodies to Human Tumor Necrosis Factor $\alpha$ : In Vitro and In Vivo Application" Cytokine Vol. 2, No. 3 (1990) pgs 162-169
✓	Tsai et al. "Responsiveness of Human T Lymphocytes to Bacterial Superantigens Presented by Cultured Rheumatoid Arthritis Synoviocytes" Arthritis & Rheumatism Vol. 39, (1996) pgs 125-136
✓	Elliott et al. "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor $\alpha$ (cA2) versus placebo in rheumatoid arthritis" The Lancet Vol. 344 (1994) pgs 1105-1110
✓	Arend et al. "Inhibition of the Production and Effects of Interleukin- $\alpha$ and tumor necrosis factor $\alpha$ in rheumatoid arthritis" Arthritis & Rheumatism Vol. 38 (1995) pgs 151-160



RECEIVED

DEC 8 8 2002  
TECH CENTER 1800/2900

✓	Rankin et al. "The therapeutic effects of an engineered human anti-tumor necrosis factor of alpha antibody (CDP571) in rheumatoid arthritis" British Journal of Rheumatology Vol. 34 (1995) pgs 334-342
✓	Storgard et al. "Decreased angiogenesis and arthritic disease in rabbits treated with an $\alpha v\beta 3$ antagonist" The Jnl. of Clinical Investigation Vol. 103 No. 1 (1999) pgs 47-54
✓	McInnes et al. "Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor $\alpha$ production in rheumatoid arthritis" Nature Medicine Vol. 3, No 2 (1997) pgs 189-195
	F.C. Breedveld "Future trends in the treatment of rheumatoid arthritis: cytokine targets" Rheumatology Vol. 38(suppl. 2) (1999) pgs 11-13
	Fava et al. "Critical role of peripheral blood phagocytes and the involvement of complement in tumour necrosis factor enhancement of passive collagen-arthritis" Clin. Exp Immunol Vol. 94 (1993) pgs 261-266
	Stupack et al. "A role for angiogenesis in rheumatoid arthritis" Braz J. Med Biol Res. Vol. 32 No. 5, (1999) pgs 573-581

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

KEIL & WEINKAUF  
1350 Connecticut Avenue, N.W.  
Washington, D.C. 20036